Synergy Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth
Canaccord Genuity Global Growth Conference 2013
NEW YORK -- August 12, 2013
Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP), a developer of new drugs to
treat gastrointestinal diseases and disorders, today announced that its
President and CEO, Gary S. Jacob, Ph.D., will present at the Canaccord Genuity
33rd Annual Growth Conference being held at the Intercontinental Hotel in
Boston, MA. The presentation is scheduled for Wednesday, August 14^th at 4:00
Live audio webcast of the presentation will be available under the investor
relations section of Synergy’s website at www.synergypharma.com. A replay of
the presentation will also be available and archived on the site for 60 days.
About Synergy Pharmaceuticals, Inc.
Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the
development of new drugs to treat patients with gastrointestinal (GI) diseases
and disorders. Synergy’s lead drug, plecanatide, and next generation
candidate, SP-333, are proprietary analogs of the natural human GI hormone,
uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”)
agonists. Plecanatide is currently in development for the treatment of chronic
idiopathic constipation and irritable bowel syndrome with constipation. SP-333
is in development to treat patients with inflammatory bowel disease and other
GI conditions.More information is available at www.synergypharma.com
Synergy Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.